PDS Biotechnology (NASDAQ:PDSB) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS

PDS Biotechnology (NASDAQ:PDSB) released its earnings results on Friday. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.02), FiscalAI reports.

PDS Biotechnology Trading Down 12.1%

PDSB traded down $0.12 during midday trading on Friday, reaching $0.86. 4,663,515 shares of the company’s stock traded hands, compared to its average volume of 8,135,308. The firm has a fifty day moving average of $0.97 and a two-hundred day moving average of $0.84. The stock has a market capitalization of $48.19 million, a price-to-earnings ratio of -1.35 and a beta of 1.16. The company has a debt-to-equity ratio of 2.73, a current ratio of 0.57 and a quick ratio of 0.57. PDS Biotechnology has a 52 week low of $0.20 and a 52 week high of $1.79.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Weiss Ratings upgraded PDS Biotechnology from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, September 28th. Wall Street Zen upgraded PDS Biotechnology from a “sell” rating to a “hold” rating in a research report on Monday, October 5th. HC Wainwright reissued a “buy” rating on shares of PDS Biotechnology in a research note on Wednesday, August 26th. Finally, B. Riley Financial restated a “buy” rating and issued a $4.00 target price (up from $3.00) on shares of PDS Biotechnology in a report on Thursday, October 29th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $9.50.

About PDS Biotechnology

PDS Biotechnology Corporation (NASDAQ:PDSB) is a clinical-stage biotechnology company focused on developing immunotherapies for cancer and infectious diseases. The company’s research is based primarily on its Versamune platform, a proprietary technology designed to stimulate targeted immune responses, including the activation of cancer-fighting T cells and natural killer cells. Its lead investigational product, PDS0101, is an immunotherapy candidate designed to target human papillomavirus type 16 (HPV16), a viral strain associated with several cancers.